Alexander Roediger, Global Lead Oncology Policy at Merck, shared a post by City Cancer Challenge (C/Can) on LinkedIn, adding:
“Improving the lives of women and lowering breast cancer deaths in low- and middle-income countries requires many partners. There are far fewer healthcare professionals – such as oncologists, pathologists, and nurses – compared to countries like Germany or the US. Access to screening, diagnosis, and care already pose major challenges.
Together with Amgen, AstraZeneca, and BMS, we have been supporting the WHO Global Breast Cancer Initiative (GBCI) and C/Can, because reducing breast cancer deaths and saving 2.5 million lives in 20 years needs many partners. More in the NCS Alliance podcast below.”
Quoting City Cancer Challenge (C/Can)‘s post:
“Through a strategic partnership with the World Health Organization and with the support of Amgen, AstraZeneca, Bristol Myers Squibb and MSD, City Cancer Challenge (C/Can) is translating the GBCI Framework into action on the ground across four cities: Tbilisi, Kumasi, Cali, and Phnom Penh. This local experience will inform future implementation in other cities and countries in the coming years.
Launched in 2021, the World Health Organization’s Global Breast Cancer Initiative (GBCI) aims to reduce breast cancer mortality by 2.5% each year: an ambition that could save 2.5 million lives over the next two decades.
Since 2023, our strategic partnership has reached 81,859 women through breast cancer care services, while strengthening local health systems by training more than 150 oncology professionals and over 300 primary care providers.
To learn more about how this collaborative model is bridging the gap between global vision and local implementation, listen to the latest NCD Alliance podcast featuring Dr. Mary Nyangasi-Onyango, MD, WHO Technical Lead for the programme, and Alexander Roediger, Associate Vice President of Global Oncology Policy at MSD.
You can also explore the key achievements of the GBCI Implementation partnership here.”
More posts featuring Alexander Roediger on OncoDaily.